Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia.
Deepak ChellapandianCameron L NicholsonPublished in: Pediatric transplantation (2019)
Myeloid neoplasms in children with sickle cell disease have been rarely reported, and the exact underlying connection between these two conditions is not clearly understood. Whether the acute myeloid leukemia in hydroxyurea-treated sickle cell patients is co-incidental or related to therapy remains an unanswered question. Herein, we report a 14-year-old girl of Haitian descent with sickle beta zero thalassemia on chronic hydroxyurea therapy who developed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia and underwent a complete disease remission following a combination chemotherapy with sorafenib and was subsequently treated using a T cell replete unmanipulated haploidentical bone marrow transplantation followed by post-transplant cyclophosphamide.
Keyphrases
- acute myeloid leukemia
- bone marrow
- tyrosine kinase
- epidermal growth factor receptor
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- mesenchymal stem cells
- sickle cell disease
- end stage renal disease
- stem cell transplantation
- cell therapy
- ejection fraction
- prognostic factors
- young adults
- low dose
- high dose
- peripheral blood
- peritoneal dialysis
- stem cells
- acute lymphoblastic leukemia
- disease activity
- patient reported
- molecular dynamics
- immune response
- replacement therapy
- ulcerative colitis